MedPath

Imaradenant

Generic Name
Imaradenant
Drug Type
Small Molecule
Chemical Formula
C15H11ClFN5
CAS Number
1321514-06-0
Unique Ingredient Identifier
770140J08A
Background

Imaradenant is under investigation in clinical trial NCT03381274 (Oleclumab (MEDI9447) Egfrm NSCLC Novel Combination Study).

Clinical Trials
Related News

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Phase 2
Completed
Conditions
Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions
First Posted Date
2020-07-31
Last Posted Date
2023-08-09
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT04495179
Locations
🇪🇸

Research Site, Madrid, Spain

A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer/DDI Study
Interventions
First Posted Date
2020-07-20
Last Posted Date
2021-01-06
Lead Sponsor
AstraZeneca
Target Recruit Count
28
Registration Number
NCT04478513
Locations
🇬🇧

Research Site, Harrow, United Kingdom

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
First Posted Date
2019-09-13
Last Posted Date
2024-04-16
Lead Sponsor
AstraZeneca
Target Recruit Count
59
Registration Number
NCT04089553
Locations
🇺🇸

Research Site, Nashville, Tennessee, United States

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Phase 1
Completed
Conditions
Advanced Solid Malignancies
Interventions
First Posted Date
2019-06-10
Last Posted Date
2020-12-08
Lead Sponsor
AstraZeneca
Target Recruit Count
10
Registration Number
NCT03980821
Locations
🇯🇵

Research Site, Kashiwa, Japan

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Phase 1
Active, not recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2017-12-21
Last Posted Date
2025-03-05
Lead Sponsor
MedImmune LLC
Target Recruit Count
43
Registration Number
NCT03381274
Locations
🇨🇳

Research Site, Taichung, Taiwan

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Phase 1
Completed
Conditions
Advanced Solid Malignancies
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Carcinoma (CRC)
Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)
Interventions
First Posted Date
2016-04-18
Last Posted Date
2023-05-26
Lead Sponsor
AstraZeneca
Target Recruit Count
313
Registration Number
NCT02740985
Locations
🇺🇸

Research Site, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy